Tech Company Financing Transactions
Taligen Therapeutics Funding Round
Taligen Therapeutics, based in Aurora, raised $65 million in investment from Alta Partners, Clarus and High Country Venture.
Transaction Overview
Company Name
Announced On
2/1/2008
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Investors
Alta Partners (Lead Investor) (Ed Hurwitz)
Clarus (Lead Investor) (Nick Galakatos)
Sanderling Ventures (Timothy Mills)
Proceeds Purpose
Timothy Mills, PhD., Chairman of the Board of Taligen said, "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12635 East Montview Blvd 223
Aurora, CO 80045
USA
Aurora, CO 80045
USA
Phone
Website
Email Address
Overview
Taligen's lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Abbie Celniker
Chief Scientific Officer
Michael Holers
President
Woodruff Emlen
Browse more venture capital transactions:
Prev: 2/1/2008: ZillionTV venture capital transaction
Next: 2/1/2008: GlobalScholar venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs